Final Program and Oral Abstracts [International Conference on AIDS (8th: 1992: Amsterdam, Netherlands)]

KEYWORD INDEX ORAL ABSTRACTS

WeB 1010, TuB0511
cysteine: MoB 0022
cytokines: TuD 0551, TuD 0552,
TuD 0548, TuD 0549, WeA 1047,
ThA 1538, WeA 1044, MoB 0019
cytomegalovirus (CMV)
infections, clinical
presentation: WeB 1054,
MoC0088
cytomegalovirus, other:
MoB 0056, MoC 0062
cytomegalovirus, retinitis:
MoA0005, WeB 1053,
WeB 1054
cytomegalovirus, treatment:
MoA 0005, MoA 0007,
WeB 1053, WeB 1054
cytopathic effect: MoA 0072
cytotoxicity, HIV: TuD0551,
MoA 0043, ThA 1538, ThA 1503,
ThA 1576
cytotoxicity, SEE Kaposi's
sarcoma: ThD 1545
D4T: WeB 1010, WeB 1011
dapsone: WeB 1017
dementia, SEE central nervous
system: ThB 1511
developing countries SEE also
geographical regions:
WeB 1084
diagnostic criteria SEE also
progression: WeB 1084
dideoxycytidine (ddC): ThA 1569,
MoB0077
dideoxyinosine (ddl): ThA 1569,
MoB 0082, MoB 0080,
MoB 0054, MoB 0079,
MoB 0055, MoB 0077,
MoB0081, MoB 0078
diphtheria toxin: TuA0524
discrimination: TuD0517,
TuD0520, TuD0518, MoDO0040,
TuD0519
drug experimentation: WeB 1019,
WeB 1015
drug use, SEE IVDU, substance
abuse: WeC 1032, WeD 1076,
WeD1077
early intervention: MoB0081,
TuD0576
education, adolescents/high
school: WeD 1069, TuD 0573,
TuD0574, ThD 1526, WeD 1071,
WeD 1072
education, elementary school:
WeD 1068, TuD 0574, TuD0576
education, evaluation: TuD 0573,
WeD 1072
education, gay/bisexual:
WeC 1029, TuD 0542, TuD 0545,
TuD 0547
education, general public:
ThC1558
education, IVDU: WeD 1076

education, other: TuD0576,
TuD0577
education, workplace: ThD 1530
electron microscopy: TuA0500
ELISA: MoAO016, ThB 1510,
MoC 0090
epidemiological methods:
WeC 1022, WeC 1090,
WeC 1026, WeC 1030
epitope analysis, env: ThA 1572,
TuA 0506, MoA 0009,
MoA 0073, ThA 1574, ThA 1575,
WeA 1000, TuB 0563, TuB 0564
epitope analysis, gag: WeA 1049,
WeA 1002, ThA 1574
epitope analysis, other: ThA 1573,
ThA 1576
Epstein Barr virus: TuA 0503
erythropoietin (EPO): TuD0548,
WeB 1012, MoA 0008
ethics: TuD0516, TuD0517
ethnography: MoC0064,
WeC 1032
Europe, general: WeC 1094
evaluation: MoA 0015, WeC 1092,
TuC0540, ThD 1526, TuD0545,
WeD 1077
exercise: WeB 1016
eyes: MoA 0005
family, impact on: MoD 0067,
MOD 0069, MoD0070,
MoD0071
feline immunodeficiency virus:
MoA0042
financing SEE also cost:
ThD1564
flow cytometry: MoA 0014
fluorothymidine (FLT): WeB 1012
foscarnet: WeB 1053, WeB 1054
ganciclovir: MoA0005, WeB 1054
gay men, drugs: ThB 1508
gay men, ethnic groups:
TuD0520
gay men, immunology:
WeA 1048, MoC0086
gay men, neuropsychology:
ThB1513
gay men, other: ThB 1543
gay men, politics: TuD 0547
gay men, prevention: WeC 1029,
TuD 0542, TuD 0543, TuD 0545,
TuD 0546, TuD 0547
gay men, progression: WeC 1027,
MoC 0083, TuC 0572, MoC 0085,
WeC 1031, MoC0065
gay men, subgroups: ThC 1518
gene products, env: WeA 1008,
WeA 1083, WeA 1079,
MoA0051, MoA 0010,
TuA 0526, TuB 0564
gene products, gag: WeC 1023,
MoA 0004, MoA 0002,
MoA 0001, WeC 1026
gene products, HIV: MoA0003

gene products, pol: MoA0004
gene products, rev: WeA 1004,
WeA 1005
gene products, tat: WeA 1005,
WeA 1006, WeA 1007,
MoB 0021
gene products, vpr: TuA0525
gene products, vpu: WeA 1008
gene products, vpx: TuA0525
general population, prevalence:
WeC 1091, WeC 1093
genome: MoA 0015, WeA 1081,
MoA 0075, TuA 0501, ThA 1533
genomic diversity: WeA 1082,
WeC 1023, TuA 0504,
WeA 1079, ThA 1534,
MoA 0051, WeA 1080,
ThA 1571, WeC 1086, WeC 1026
geographical regions, AFRICA:
WeC 1066, TuB 0565
geographical regions,
AUSTRALIA/NEW ZEALAND:
TuD 0545
geographical regions, MIDDLE
EAST: WeA 1083
geographical regions SEE also
gay men, IVDU, prostitutes,
developing countries:
WeC 1023
glutathione: MoB 0022
GM-CSF: MoA0005
gp 120, binding: MoA0074,
MoA0047, MoA 0050,
WeA 1000, MoB 0020
gp 120, human monoclonal:
TuA 0506, WeA 1000
gp 120, other: MoA0011,
TuA 0504, WeA 1046, TuB 0564
gp 160: MoA0011, MoA0009,
TuB 0562, TuB 0563, MoB 0024
Guatemala:
gynecology: TuB 0530, TuB 0532,
MoC0034
Haiti: WeC 1087
health beliefs: ThD 1530
health care, organization:
MoD 0070
health care personnel, other:
TuC 0568, WeD 1070
health care personnel, risks to:
MoD 0036
hematological abnormalities:
TuD 0548, MoA0008
hematopoiesis: TuD 0548,
MoA 0006
hemophilia, epidemiology:
WeC 1026
hemophilia, progression:
MoC 0062
hemophilia, seroconversion:
WeA 1083
herpes viruses: TuA0524,
ThB 1548, WeB 1056
heterosexual, prevalence:

ThC 1517, MoC0028, ThC 1561,
WeC 1089
heterosexual, prevention:
WeC 1085, TuD0575, ThD 1528
heterosexual, SEE sexual
behavior: ThC 1514, WeC 1089,
WeD 1075
heterosexual, SEE transmission:
MoC 0029, ThC 1514, WeC 1087,
WeC 1088, WeC 1089
high risk groups, combined SEE
also gay men, hemophilia,
IVDU, geographical regions: hB
1513
HIV antigen, assay:, TuA 0500,
ThA 1504, WeB 1010, ThC 1579
HIV antigenemia: ThA 1573,
TuA 0555, WeB 1010,
WeB 1011, TuB 0511, ThC 1579
HIV, AZT: TuA0521, MoB0082,
MoB0080, ThB 1549
HIV, biopsy: TuD0549
HIV, children: TuB0513
HIV, flow cytometry, SEE gp
120: MoA0014
HIV, immune complexes:
TuA0554
HIV, infectivity: MoA0076,
MoA0047, TuA0525, ThA 1532,
TuB 0515, WeC 1064, TuC0570
HIV, lung: TuB0533, TuB0536,
WeB 1021
HIV, monitor: MoAO014,
TuA0556, TuA0558
HIV, other: WeA 1044, TuA 0558,
ThB 1543, TuB0538, TuC0569
HIV, pregnancy: WeC 1063,
WeC 1059, ThC 1581, MoD0068
HIV, prognosis: TuA0559,
WeC 1027, MoC 0083
HIV, seroconversion: WeA 1048,
TuA 0500, ThC 1552, MoC 0085,
ThC 1559, TuC 0566, MoD 0038
HIV-2, association with other
HIV/HTLV: WeC 1067
HIV-2, disease: WeA 1080,
WeC 1066
HIV-2, natural history: WeA 1080,
WeC 1066
HIV-2, other: MoA0049,
WeC 1065, WeC 1066
HIV-2, seroprevalence: ThC 1551,
WeC 1067
HIV-2, transmission: WeC 1063,
WeC 1064, WeC 1065
HIV-immunogen: WeD 1039,
MoA0010, TuB 0564
HIV-lscom: MoA0018
HIV-specific active
immunotheraphy (HSAI):
TuB 0560
HLA, expression: MoB 0024
HLA: ThA 1536, MoA0018,
MoC 0087

108